This article was originally published in Start Up
Bacterial cellulose used in the pulp and paper industry has found a new home in the creation of artificial blood vessels for cardiovascular repair. The synthetic material from Sweden's Arterion AB is noteworthy because it appears to function well in small-diameter bypass surgery. The replacement vascular graft also avoids the drawbacks of harvesting veins from the legs and arms. The company believes it can tailor the material to nearly any shape or mechanical property.
You may also be interested in...
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Rare Disease Research: Where Compassion Meets Commerce," features profiles of Afraxis, bluebird bio, Edimer Pharmaceuticals and Ultragenyx Pharmaceutical. Plus these Start-Ups Across Health Care: AirXpanders, Arterion, CortiCare and Sirius Implantable Systems.
Work related to the European Commission’s promise to assess the impact of the Medical Device Regulation, including its impact on innovation, is starting to take shape.